Gender-Affirming Hormone Therapy (GAHT)
Gender-affirming hormone therapy (GAHT) encompasses feminizing regimens (estrogen ± antiandrogens) and masculinizing regimens (testosterone) used to align physical characteristics with gender identity. The Endocrine Society 2017, WPATH Standards of Care Version 8 (2022), ACOG 2021, and AAFP 2023 all recognize GAHT as medically necessary care that improves psychological functioning, quality of life, and reduces gender dysphoria.[1][2][3][4]
This article is the pharmacology reference for the reconstructive urologist and urogynecologist who participates in GAHT-management decisions perioperatively or longitudinally. For surgical detail, see Gender-Affirming Surgery overview. For related hormonal-therapy topics, see Testosterone replacement, Vaginal and topical estrogen, and Androgen adjuncts.
Feminizing GAHT — estrogen ± antiandrogen
Estrogen formulations
The primary agent is 17β-estradiol. Avoid ethinyl estradiol; SOC 8 also advises against conjugated estrogens when estradiol is available. Historical cohorts using older regimens reported high VTE rates, but the approximately 20-fold signal is not a direct modern head-to-head estimate for ethinyl versus transdermal estradiol.[26][1][5][3]
| Formulation | Dose | Route | Notes |
|---|---|---|---|
| Oral estradiol | 2–6 mg/day, individualized gradual titration | PO | Most commonly prescribed; higher VTE risk than transdermal[1][5] |
| Transdermal estradiol | 0.025–0.2 mg/24 h patch (SOC 8 range)[26] | Transdermal | Preferred for age >45, smokers, VTE risk factors, BMI >30[1][5] |
| Estradiol valerate | 2–10 mg IM weekly or 5–30 mg every 2 weeks (published range; titrate to avoid excessive peaks) | IM / SC | Peak/trough variation; comparative VTE risk is not established[1] |
| Estradiol cypionate | 2–10 mg IM q1–2 wk | IM / SC | Similar to valerate[1] |
| Ethinyl estradiol | — | — | Do not use — increased thrombotic risk; standard estradiol assays do not monitor this drug[3] |
| Conjugated estrogens | — | — | Not recommended — monitoring impossible; higher thrombotic risk[3] |
Target serum levels (Endocrine Society):[1][5]
- Estradiol 100–200 pg/mL (wider range may be acceptable for individual goals)
- Testosterone <50 ng/dL
Antiandrogen agents
Estrogen alone is usually insufficient to suppress testosterone into the female range — adjunctive antiandrogen is standard.[1]
| Agent | Dose | Mechanism | Key considerations |
|---|---|---|---|
| Spironolactone | 100–300 mg/day in divided doses (SOC 8 range)[26] | AR antagonist; weak T-synthesis inhibitor | US first-line; monitor K⁺ (hyperkalemia rare in healthy adults); weak estrogenic activity[1][5][3] |
| Cyproterone acetate | 10 mg/day in SOC 8; use lowest effective dose[26] | Progestational antiandrogen; suppresses gonadotropins | Used in some non-US settings; not approved in the US. Cumulative-dose meningioma risk and hepatotoxicity require attention; hyperprolactinemia does not by itself establish prolactinoma[28][1][4] |
| GnRH agonists (leuprolide, goserelin) | Product- and indication-specific depot dosing | Suppress LH/FSH → profound T suppression | Most effective suppression; very expensive in US; used by specialist teams for puberty suppression; adult depot schedules are not automatically pediatric schedules[1][5] |
| Finasteride | 1–5 mg/day | 5α-reductase inhibitor (T → DHT block) | Does not lower T; useful for scalp-hair and body-hair goals once T is already suppressed[5][3] |
| Progesterone / progestins | Variable | Gonadotropin suppression | Anecdotal breast-development and mood benefit; no well-designed studies; MPA has WHI CV signal[6] |
Timeline of feminizing changes[1][5]
| Change | Onset | Max effect | Reversibility |
|---|---|---|---|
| Breast growth | 3–6 mo | 2–3 y | Irreversible |
| Decreased libido / erections | 1–3 mo | 3–6 mo | Reversible |
| Skin softening / ↓ oiliness | 3–6 mo | Unknown | Reversible |
| Fat redistribution (female) | 3–6 mo | 2–5 y | Reversible |
| Decreased body / facial hair | 6–12 mo | >3 y (usually needs laser / electrolysis) | Reversible |
| Decreased muscle mass / strength | 3–6 mo | 1–2 y | Reversible |
| Testicular-volume reduction | 3–6 mo | 2–3 y | Recovery and fertility after cessation are variable; not guaranteed |
| Male-pattern baldness (slowing) | 1–3 mo | 1–2 y | Variable |
| Voice | — | — | N/A — estrogen does not raise pitch; speech therapy required |
Masculinizing GAHT — testosterone
Regimens mirror the treatment of male hypogonadism but target the normal physiologic male range (320–1,000 ng/dL).[1][5] See also Testosterone replacement for the underlying pharmacology.
Testosterone formulations
| Formulation | Dose | Route | Notes |
|---|---|---|---|
| Cypionate | 50–100 mg SC/IM weekly (or 100–200 mg q2 wk) | SC or IM | US first-line; SC increasingly preferred (smaller needle, less pain)[5][3] |
| Enanthate | 50–100 mg SC/IM weekly (or 100–200 mg q2 wk) | SC or IM | Interchangeable with cypionate[1][5] |
| Undecanoate | US AVEED: 750 mg IM at baseline, 4 weeks, then every 10 weeks; 1,000 mg regimens belong to other products/jurisdictions | IM only | US REMS; observe 30 minutes after every AVEED injection for POME/anaphylaxis. GAHT use is off-label.[27] |
| Transdermal gel / patch | Gel 50–100 mg/d; patch 2.5–7.5 mg/d | Transdermal | More uniform levels; titrate to clinical goals and measured levels; transfer risk to contacts[1][5] |
| Pellets | 150–450 mg SC q3–6 mo | SC implant | Less common; requires minor procedure[5] |
- Testosterone 320–1,000 ng/dL (for injectable esters, measure midway between injections; target 400–700 ng/dL)
- Avoid supraphysiologic levels — erythrocytosis, acne, adverse lipid profile
Timeline of masculinizing changes[1][5]
| Change | Onset | Max effect | Reversibility |
|---|---|---|---|
| Cessation of menses | 2–6 mo | — | Reversible |
| Clitoral enlargement | 3–6 mo | 1–2 y | Irreversible |
| Voice deepening | 3–12 mo | 1–2 y | Irreversible |
| Facial / body hair growth | 6–12 mo | 4–5 y | Irreversible |
| Increased muscle mass | 6–12 mo | 2–5 y | Reversible |
| Fat redistribution (male) | 3–6 mo | 2–5 y | Reversible |
| Acne | 1–6 mo | 1–2 y | Reversible |
| Increased libido | 1–3 mo | Variable | Reversible |
| Male-pattern baldness | 6–12 mo | Variable | Irreversible (genetic) |
| Vaginal atrophy | 3–6 mo | 1–2 y | Reversible |
Persistent bleeding requires assessment of adherence, hormone levels, pregnancy risk, and other gynecologic causes. A progestational agent may be considered when appropriate; endometrial ablation is not a routine pharmacologic escalation and requires separate fertility and procedural counseling.[1][5]
Puberty suppression in adolescents
GnRH agonists can suppress further pubertal development from Tanner stage 2 in eligible adolescents after specialist assessment and individualized informed consent. Adult GAHT regimens should not be used as pediatric prescribing instructions.[26][1][7][8]
Rationale
- Prevents irreversible development of undesired secondary sex characteristics (breast development, voice deepening, facial hair, skeletal changes)
- Extends the diagnostic window for gender-identity exploration
- May relieve distress from unwanted pubertal changes; psychological outcome estimates come mainly from observational studies and do not establish a uniform causal reduction in suicidality
- Improves cosmetic outcomes if the patient later proceeds to GAHT
Key considerations
- Suppression of the hypothalamic-pituitary-gonadal axis is reversible after stopping; this does not mean every downstream developmental outcome is known to be fully reversible
- Bone mineral density declines during treatment (particularly in AMAB individuals); may improve with subsequent hormones, but recovery is not uniform across sites or populations
- Fertility implications — GnRHa inhibits spermatogenesis and ovulation; fertility preservation counseling before initiation
- Growth — height velocity slows during treatment; final height generally within genetic target
Signal from real-world data
Nos 2022 (JAMA Network Open) included 434 adolescents, 70 of whom received GnRHa. Median time to GAHT was 1.8 versus 1.0 years with versus without GnRHa. This observational association does not establish that blockers cause delay, determine future identity, or eliminate individual uncertainty.[9]
Cardiovascular and thromboembolic risk — the dominant safety concern
Feminizing GAHT — VTE
Transfeminine persons on estrogen have higher VTE incidence than cisgender women or cisgender men; risk varies by age, formulation, exposure duration, and baseline factors. Much of the historical signal reflects ethinyl estradiol — which is no longer recommended. Transdermal estradiol has a substantially better risk profile.[10]
van Zijverden2025 online/2026 print Dutch cohort (n = 2,714 transfeminine; 23,907 person-years):[11]
- MI: SIR 0.50 (95% CI 0.32–0.71) — lower than general-population men
- Stroke: SIR 0.94 (0.72–1.19) — similar
- VTE: SIR 1.81 (1.33–2.35) — higher
Masculinizing GAHT — CV
Same Dutch cohort (n = 1,617 transmasculine; 13,457 person-years):[11]
- MI: SIR 4.20 (2.72–6.01) — significantly higher than general-population women
- Stroke: SIR 1.55 (1.01–2.20) — higher
- VTE: SIR 1.00 (0.53–1.61) — similar
Testosterone is also associated with erythrocytosis (most common AE), adverse lipid profile (↓HDL, ↑LDL), and higher BP.[1][3][12]
Historical perioperative protocols varied; use current multidisciplinary guidance for the individual operation.[13][26]
Risk-mitigation
- Transdermal estradiol over oral for age >45, smokers, BMI >30, VTE risk[5][10]
- Avoid ethinyl estradiol and conjugated estrogens entirely[1][10]
- Smoking cessation strongly encouraged[5]
- Monitor hematocrit in transmasculine patients — target <54%; reduce dose or investigate if higher[1][3]
- Individualize perioperative hormones with the surgeon and prescriber. SOC 8 does not support a universal 4–6-week interruption; weigh VTE risks, prophylaxis, and consequences of withdrawal, particularly after gonadectomy.[26]
- Standard CV risk-factor management (lipids, BP, diabetes screening)[1][12]
Monitoring protocols
Feminizing GAHT[1][5]
| Parameter | Frequency | Target / action |
|---|---|---|
| Serum estradiol | q3 mo × 1 y, then 1–2×/y | 100–200 pg/mL |
| Serum testosterone | q3 mo × 1 y, then 1–2×/y | <50 ng/dL |
| Potassium (if on spironolactone) | q3 mo × 1 y, then annually | Monitor for hyperkalemia |
| Prolactin | Periodically | Monitor for prolactinoma (rare) |
| Fasting lipids, glucose / HbA1c | Baseline then periodically | Standard CV-risk assessment |
| LH | Consider at follow-ups | Helps assess gonadal suppression |
| CBC | Baseline then annually | Hemoglobin may decrease |
| BMD | Baseline if risk factors; age 60 if low-risk; after gonadectomy without hormone replacement | Osteoporosis screening |
Masculinizing GAHT[1][5]
| Parameter | Frequency | Target / action |
|---|---|---|
| Serum testosterone | q3 mo × 1 y, then 1–2×/y | 400–700 ng/dL (midway between ester injections) |
| Hematocrit / hemoglobin | q3 mo × 1 y, then 1–2×/y | Hct <54%; reduce dose or investigate if higher |
| Fasting lipids | Baseline then periodically | ↓ HDL, ↑ LDL / TG expected |
| Weight, BP | Every visit | Hypertension and weight gain surveillance |
| BMD | If T discontinued, non-compliant, or risk factors | Osteoporosis screening |
| Cervical screening (if cervix present) | Per ACOG | T-induced atrophy → 10× higher unsatisfactory Pap rate; self-collected HPV may be preferable[3] |
Cancer screening — screen organs present, not identity
Screening is based on the anatomy present, regardless of gender identity.[14][15][16]
Breast
- Transfeminine — breast cancer incidence is lower than cisgender women (~4.1 vs 155 per 100,000 person-years) but higher than cisgender men. Screening timing varies by guideline and risk: ACR considers mammography/DBT appropriate to discuss from age 40 after ≥5 years of hormones; use an individualized local screening pathway.[29] Dense breast tissue (60%) may increase false negatives.[14][15]
- Transmasculine — if breast tissue remains (reduction mammoplasty, not mastectomy), follow cisgender female guidelines. After mastectomy, limited data support routine screening beyond clinical chest exam.[15]
Cervical
All individuals with a cervix should follow standard screening guidelines. Transmasculine patients have lower screening rates due to discomfort and structural barriers; testosterone-induced atrophy drives a 10-fold higher rate of unsatisfactory Paps. Self-collected HPV testing may improve adherence.[14][3]
Prostate
Transfeminine patients retain their prostate regardless of surgery. PSA is substantially lowered by feminizing GAHT — median 0.02 ng/mL in one series. PSA 1ng/mL is a proposed concern threshold in androgen-suppressed patients, not a prospectively validated universal normal limit; rising PSA warrants attention. Standard age-appropriate shared decision-making applies.[14][16][17]
Fertility preservation — counsel before initiating
Transfeminine
- Estrogen + antiandrogens cause increased sperm abnormalities, reduced count and motility, or azoospermia. Spermatogenesis may partially recover after cessation but is not guaranteed[18][19]
- Sperm cryopreservation should be offered before starting GAHT[4][20]
Transmasculine
- Testosterone causes ovarian cortical / stromal changes but persistent folliculogenesis is observed in most studies. Successful oocyte stimulation, fertilization, and live birth have been reported both with and without T discontinuation[18]
- Oocyte or embryo cryopreservation should be offered before starting GAHT[4][20]
- Testosterone is NOT reliable contraception — pregnancies have occurred during T therapy[5][4]
- Discontinue T before a planned pregnancy until after delivery and any chest-feeding[4]
Urologic considerations
Feminizing GAHT
- Decreased erectile function and testicular atrophy are expected[5]
- Prostate undergoes atrophy over time (diffuse atrophy + basal-cell hyperplasia on histology)[15]
- After vaginoplasty, the shortened neourethra is generally uneventful, but urinary complications can occur[21]
Masculinizing GAHT
- Vaginal atrophy is common — dyspareunia, dryness, and urinary symptoms[5][22]
- da Silva 2024 cross-section (n = 68 transmasculine on T) — 94.1% reported at least one pelvic-floor symptom in this selected cross-sectional sample, not a population prevalence or proof of testosterone causation: storage symptoms 69.1%, sexual dysfunction 52.9%, anorectal symptoms 45.6%, urinary incontinence substantial[22]
- After phalloplasty, urethral lengthening drives fistulae, strictures, meatal stenosis, and post-voiding dribble — see the reconstructive literature[21]
Bone health
- Feminizing: adequate estrogen maintains BMD. Screen at baseline if risk factors; at age 60 if low-risk; after gonadectomy without hormone replacement[1]
- Masculinizing: adequate testosterone maintains BMD. Screen if T discontinued, non-compliant, or other risk factors[1]
- GnRHa in adolescents: BMD Z-scores can decline during suppression; subsequent recovery varies, and long-term skeletal outcomes need continued follow-up[8]
Drug interactions
| Interaction | Effect | Practical |
|---|---|---|
| Boosted PI antiretrovirals | May decrease estradiol and increase T | Adjust monitoring; check levels[23] |
| NNRTIs (efavirenz, etravirine, nevirapine) | May decrease both estradiol and T | Same — monitor[23] |
| Spironolactone + ACE-I / ARB / K⁺ supp / NSAIDs | Hyperkalemia | Monitor K⁺[1] |
| Smoking | Increases VTE risk synergistically with estrogen | Strongly encourage cessation[5] |
| Perioperative | No universal estrogen hold; testosterone usually continues unless a patient-specific concern | Coordinate hormones and VTE prophylaxis[26] |
Mental-health outcomes
Multiple longitudinal and cross-sectional studies demonstrate that GAHT is associated with:[24][8]
- Reduced depression, anxiety, suicidality
- Improved global psychological functioning
- Improved QoL and body satisfaction
- Reduced gender dysphoria
The 2019 NEJM review (Safer & Tangpricha) summarized that gender-affirming care — including hormone therapy — is supported by multiple medical societies as medically necessary treatment that improves well-being.[3]
Evidence Summary
| Domain | Evidence level | Key source |
|---|---|---|
| Guideline framework | Professional guidance; recommendation-specific certainty | Endocrine Society 2017[1]; WPATH SOC 8[26]; ACOG 2021[2] |
| Feminizing regimens and targets | Level 2 | Goldstein 2025[5]; Safer 2019[3] |
| Masculinizing regimens and targets | Level 2 | Endocrine Society[1]; Irwig 2017[25] |
| Puberty suppression | Level 2 | Tornese 2025 SR[8]; Nos 2022[9] |
| CV and VTE risk | Level 2 (large cohort) | van Zijverden2025 online/2026 print Dutch cohort[11]; Skeith 2026 NEJM review[10] |
| Fertility preservation | Level 2 | De Roo 2025 systematic review[18] |
| Pelvic-floor dysfunction on testosterone | Level 3 | da Silva 2024[22] |
| Cancer screening | Level 3 (consensus) | Leone 2023 JAMA Oncol[14]; NCCN[15][17] |
Clinical Positioning
- Use 17β-estradiol, never ethinyl estradiol or conjugated estrogens — the historical VTE signal largely traces to ethinyl estradiol, and monitoring requires 17β-estradiol assays.[1][10]
- Prefer transdermal estradiol in patients >45 y, smokers, BMI >30, or with VTE risk factors. Oral is acceptable in low-risk patients, with full informed consent.[5][10]
- Spironolactone is US first-line antiandrogen; GnRH agonist is the most effective T-suppression; cyproterone is the European standard but unavailable in the US and carries meningioma / hepatotoxicity flags.[1]
- Testosterone in transmasculine adults mirrors male-hypogonadism care — target 400–700 ng/dL midway between ester injections; hematocrit is the dose-limiting lab at >54%.[1]
- Testosterone is NOT contraception. Counsel explicitly and provide contraception separately if pregnancy avoidance is desired.[4][5]
- Fertility-preservation counseling must precede GAHT initiation — sperm cryopreservation (transfeminine) or oocyte / embryo cryopreservation (transmasculine). See Androgen adjuncts for the post-treatment fertility-recovery armamentarium.[4][18]
- Cancer screening follows anatomy, not identity. Prostate, cervix, and breast all require organ-based screening. PSA interpretation must account for androgen suppression; no universally validated threshold exists.[14][16]
- Risk differs by event and comparator — the Dutch observational cohort shows a ~4× MI-risk elevation in transmasculine patients (vs cis women) and a ~1.8× VTE-risk elevation in transfeminine patients (vs general-population men). These are associations, not causal estimates of GAHT alone. Actively manage traditional CV risk factors alongside GAHT.[11][12]
- Perioperative management requires a joint plan, including hormone formulation, prior VTE, immobility, prophylaxis, and effects of withdrawal. Routine cessation for every patient is not established.[26]
- Ask about pelvic-floor and genital symptoms and treat the identified condition. A small selected cross-sectional sample cannot establish nearly universal dysfunction or justify treatment in asymptomatic people.[22]
- Adolescent treatment needs specialist assessment, fertility counseling, and discussion of uncertainty. Nos 2022 is an observational treatment-timing study, not proof of causation or complete developmental reversibility.[9]
- Monitoring cadence is q3 months in year 1, then 1–2×/year for both feminizing and masculinizing regimens, with the parameters above.[1][5]
See Also
- Vaginal and topical estrogen
- Vaginal DHEA
- Ospemifene
- Testosterone replacement
- Androgen adjuncts — fertility-preserving alternatives
References
1. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. "Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline." J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658
2. American College of Obstetricians and Gynecologists. Health care for transgender and gender-diverse individuals. Cronin B, Stockdale CK. ACOG; 2021.
3. Safer JD, Tangpricha V. "Care of transgender persons." N Engl J Med. 2019;381(25):2451–2460. doi:10.1056/NEJMcp1903650
4. Dakkak M, Kriegel DL, Tauches K. "Caring for transgender and gender-diverse people: guidelines from WPATH." Am Fam Physician. 2023;108(6):626–629.
5. Goldstein Z, Krasowski MD, Greene DN. "Gender-affirming feminizing hormone therapy." JAMA Intern Med. 2025;185(8):1027–1028. doi:10.1001/jamainternmed.2025.1161
6. Crandall CJ, Mehta JM, Manson JE. "Management of menopausal symptoms: a review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140
7. Turban JL, Thornton J, Ehrensaft D. "Biopsychosocial assessments for pubertal suppression to treat adolescent gender dysphoria." J Am Acad Child Adolesc Psychiatry. 2025;64(1):12–16. doi:10.1016/j.jaac.2024.03.016
8. Tornese G, Di Mase R, Munarin J, et al. "Use of gonadotropin-releasing hormone agonists in transgender and gender-diverse youth: a systematic review." Front Endocrinol. 2025;16:1555186. doi:10.3389/fendo.2025.1555186
9. Nos AL, Klein DA, Adirim TA, et al. "Association of gonadotropin-releasing hormone analogue use with subsequent use of gender-affirming hormones among transgender adolescents." JAMA Netw Open. 2022;5(11):e2239758. doi:10.1001/jamanetworkopen.2022.39758
10. Skeith L, Bates SM. "Sex hormone influences on venous thrombotic and cardiovascular risk." N Engl J Med. 2026;394(15):1514–1528. doi:10.1056/NEJMra2202438
11. van Zijverden LM, Thijs A, van Diemen JJK, Wiepjes CM, den Heijer M. "Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study." Eur Heart J. 2026;47(21):2660–2669; online 2025. doi:10.1093/eurheartj/ehaf837
12. Glintborg D, Christensen LL, Andersen MS. "Transgender healthcare: metabolic outcomes and cardiovascular risk." Diabetologia. 2024;67(11):2393–2403. doi:10.1007/s00125-024-06212-6
13. Rosendale N, Goldman S, Ortiz GM, Haber LA. "Acute clinical care for transgender patients: a review." JAMA Intern Med. 2018;178(11):1535–1543. doi:10.1001/jamainternmed.2018.4179
14. Leone AG, Trapani D, Schabath MB, et al. "Cancer in transgender and gender-diverse persons: a review." JAMA Oncol. 2023;9(4):556–563. doi:10.1001/jamaoncol.2022.7173
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines: genetic / familial high-risk assessment — breast, ovarian, pancreatic, and prostate. Updated 2026-02-19.
16. National Comprehensive Cancer Network. NCCN clinical practice guidelines: prostate cancer early detection. Updated 2026-02-18.
17. Leone AG, Casolino R, Trapani D, et al. "Position paper of the Italian Association of Medical Oncology on health disparities among transgender and gender-diverse people: the Assisi Recommendations." EClinicalMedicine. 2023;65:102277. doi:10.1016/j.eclinm.2023.102277
18. De Roo C, Schneider F, Stolk THR, et al. "Fertility in transgender and gender-diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility." Hum Reprod Update. 2025;31(3):183–217. doi:10.1093/humupd/dmae036
19. Ainsworth AJ, Allyse M, Khan Z. "Fertility preservation for transgender individuals: a review." Mayo Clin Proc. 2020;95(4):784–792. doi:10.1016/j.mayocp.2019.10.040
20. Schwartz AR, Moravek MB. "Reproductive potential and fertility preservation in transgender and nonbinary individuals." Curr Opin Obstet Gynecol. 2021;33(4):327–334. doi:10.1097/GCO.0000000000000729
21. Trum HW, Hoebeke P, Gooren LJ. "Sex reassignment of transsexual people from a gynecologist's and urologist's perspective." Acta Obstet Gynecol Scand. 2015;94(6):563–567. doi:10.1111/aogs.12618
22. da Silva LMB, Freire SND, Moretti E, Barbosa L. "Pelvic floor dysfunction in transgender men on gender-affirming hormone therapy: a descriptive cross-sectional study." Int Urogynecol J. 2024;35(5):1077–1084. doi:10.1007/s00192-024-05779-3
23. Horberg M, Thompson M, Agwu A, et al. "Primary care guidance for providers of care for persons with HIV: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America." Clin Infect Dis. 2024;ciae479. doi:10.1093/cid/ciae479
24. T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. "Endocrinology of transgender medicine." Endocr Rev. 2019;40(1):97–117. doi:10.1210/er.2018-00011
25. Irwig MS. "Testosterone therapy for transgender men." Lancet Diabetes Endocrinol. 2017;5(4):301–311. doi:10.1016/S2213-8587(16)00036-X
26. Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. 2022. Full guideline. doi:10.1080/26895269.2022.2100644.
27. AVEED US prescribing information. DailyMed.
28. EMA. Restrictions in use of cyproterone due to meningioma risk. 2020. Safety communication.
29. ACR. Transgender Breast Cancer Screening. Appropriateness Criteria.